Insider Transactions in Q3 2024 at Theravance Biopharma, Inc. (TBPH)
Insider Transaction List (Q3 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 20
2024
|
Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY |
SELL
Payment of exercise price or tax liability
|
Direct |
9,268
-2.63%
|
$74,144
$8.22 P/Share
|
|
Aug 20
2024
|
Aine Miller SVP, DEV & HEAD OF IRE OFFICE |
SELL
Payment of exercise price or tax liability
|
Direct |
5,201
-3.14%
|
$41,608
$8.22 P/Share
|
|
Aug 20
2024
|
Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
8,635
-2.62%
|
$69,080
$8.22 P/Share
|
|
Aug 20
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
15,997
-0.87%
|
$127,976
$8.22 P/Share
|
|
Aug 20
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Payment of exercise price or tax liability
|
Direct |
9,222
-2.74%
|
$73,776
$8.22 P/Share
|
|
Aug 07
2024
|
Rick E Winningham CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,252
+0.18%
|
$22,764
$7.83 P/Share
|
|
Aug 07
2024
|
Eli Samaha > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
999,800
+9.51%
|
$6,998,600
$7.8 P/Share
|
|
Jul 10
2024
|
Rhonda Farnum SVP, COMM & MEDICAL AFFAIRS |
SELL
Open market or private sale
|
Direct |
4,000
-1.18%
|
$36,000
$9.0 P/Share
|